Biomarker testing in suspected pre-eclampsia

Hypertensive disorders, such as pre-eclampsia (PE), affect approximately 13.5% of pregnancies in the UK, which equates to around 80,000 women. Uncertainty in diagnosis of, and prognosis in, PE may lead to late diagnosis or, more frequently, unnecessary hospitalisation of women who do not go on to develop the condition. Therefore, there is an unmet medical need for short-term prediction or rule-out of the condition in pregnant women with suspected PE. A disease-specific biomarker accurately predicting maternal and neonatal complications in suspected PE cases would facilitate the decision-making of clinicians regarding monitoring and treatment.

This story is Premium Content and is only available to registered users. If you don't already have an account, please register with us completely free of charge.

Other news

Upcoming Events

Pathology Horizons 2018 Conference

Lough Erne Resort, Co. Fermanagh, Northern Ireland
September 13-15

Microbe 2018

Hilton Hotel, Sheffield
21-23 September 2018

World Congress of the International Federation of Biomedical Laboratory Science (IFBLS)

Palazza dei Congressi of Firenze
22-26 September 2018

Infection Prevention 2018

Scottish Events Campus, Glasgow
30 September - 2 October 2018

Going Overboard with Microbiology - Women and Children First

Merseyside Maritime Museum, Albert Dock, Liverpool
19 October 2018

Latest Issue

Pathology In Practice

Pathology In Practice

Jun 2018

Biomarker testing in suspected pre-eclampsia

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.